
Case Report

Autoimmune hepatitis with giant-cell transformation

José Estradas; Virginia Pascual-Ramos; Braulio Martínez; Misael Uribe; Aldo Torre

Abstract

Background/Aims: Giant-cell hepatitis (GCH), also known as postinfantile or syncytial giant cell hepatitis, is a frequent pattern of liver injury in the neonate, primarily seen in the first three months of life. Few cases in adults have been reported, some of them associated to autoimmune diseases such as autoimmune hepatitis. Methods: We present a case of autoimmune hepatitis with giant cell transformation in a 39 year old male with polyarthritis. We discuss his clinical presentation and course. We made a review of the literature of agents associated to this diagnosis, the mechanisms involved in the formation of giant hepatocytes, the histological findings, clinical course, treatment options and prognosis of this rare entity. Results and conclusions: In conclusion, the clinical course varies from normalization of hepatic histology to progression to cirrhosis and liver failure. The prognosis is dictated by the underlying liver disease and in the setting of autoimmune hepatitis the clinical course is usually severe with most of the patients progressing to cirrhosis. Prolonged treatment with corticosteroids and immunosuppressants is usually effective in rendering the cirrhosis inactive.

Key words: Autoimmune hepatitis, giant-cell hepatitis, postinfantile giant cell hepatitis, syncytial giant cell hepatitis.

Case report

Giant-cell hepatitis (GCH), also known as postinfantile or syncytial giant cell hepatitis, is a frequent pattern of liver injury in the neonate, primarily seen in the first three months of life. Few cases in adults have been reported, some of them associated to autoimmune diseases such as autoimmune hepatitis.

We herein present a case of autoimmune hepatitis with giant cell transformation in a 39 year old male with polyarthritis involving the shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints, knees, ankles and metatarsophalangeal joints. He had a 5 month history of asthenia, weight loss (20 kg), dry cough and morning stiffness. He admitted taking non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief.

On physical examination the patient was found cachectic with arthritis of the mentioned joints. Neither hepatomegaly nor tenderness on the right upper quadrant was found on palpation.

Laboratory studies showed WBC 18.8 K/μL, hemoglobin 12.1 g/dL, platelets 611 K/μL, ALT 74 U/L, AST 59 U/L, GGT 158 U/L, bilirubins were within normal limits, alkaline phosphatase was of 226 U/L, albumin 2.76 g/dL, and globulines of 3.94.

The rheumatoid factor (nephelometry) was slightly positive: 40.51 UI/mL, anti-cyclic citrullinated peptide autoantibody (2nd generation ELISA) and antinuclear antibodies (immunofluorescence) were both negative, anti-neutrophil cytoplasmic autoantibodies (ANCAs) (immunofluorescence) showed a c-ANCA pattern in a title of 1:320 with negative myeloperoxidase and proteinase-3 (ELISA). Serum levels of complement were decreased (C3 59.5 mg/dL, C4 9.0 mg/dL), the viral profile was negative.

The rheumatoid factor (nephelometry) was slightly positive: 40.51 UI/mL, anti-cyclic citrullinated peptide autoantibody (2nd generation ELISA) and antinuclear antibodies (immunofluorescence) were both negative, anti-neutrophil cytoplasmic autoantibodies (ANCAs) (immunofluorescence) showed a c-ANCA pattern in a title of 1:320 with negative myeloperoxidase and proteinase-3 (ELISA). Serum levels of complement were decreased (C3 59.5 mg/dL, C4 9.0 mg/dL), the viral profile was negative.

The chest X ray showed an apparent widening of the mediastinum, a chest CT was performed and showed a nodular lesion with central necrosis in the anterior mediastinum and mediastinal adenomegalies. The mediastinal mass was found to be an atypical thymoma type B3 (World Health Organization Classification) after the surgical excision and pathological examination were performed, radiotherapy was indicated afterwards.

He was started on chloroquine, sulfasalazine and prednisone which relieved the rheumatologic symptoms, but after 6 months of treatment he became jaundiced and had

1 Department of Gastroenterology.
2 Department of Rheumatology and Immunology.
3 Department of Pathology.

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Address for correspondence:
Aldo Torre, MD. M.Sc.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Vasco de Quiroga 15, Section XVI, Tlalpan, Mexico City
Telephone: +55 5573 3418
Fax: +55 5655 0942
E-mail: detoa@yahoo.com

Manuscript received and accepted:
10 September and 27 November, 2008
a progressive increment of bilirubins (total bilirubins 11.2 mg/dL, direct bilirubins 6.4 mg/dL) and transaminases (ALT: 523 U/L, AST: 187 U/L). Serum globulines were within normal range and anti-mitochondrial antibodies were negative. Drug toxicity, biliary tract disease and infectious causes were excluded.

A liver biopsy was performed and showed interface hepatitis with mild portal and periportal lymphoplasmacytic inflammation, hepatocyte swelling and necrosis (Figure 1). Giant multinucleated hepatocytes were present in more than 50% of the biopsy, predominantly in periportal area (Figure 2); other histological findings were mild lobular inflammation, necrosis and mild interlaminar fibrosis. The diagnosis of autoimmune hepatitis with giant cell transformation was concluded.

The final «Autoimmune Hepatitis Score» for the diagnosis of autoimmune hepatitis was: 20.1

He was started on prednisone 40 mg and azathioprine 100 mg daily, he has been attending our clinic for regular check-ups and his clinical and biochemical profile have markedly improved after one year of treatment.

Giant cell hepatitis (GCH) is an infrequent presentation of liver injury in the adulthood. It is more commonly described in neonates as a response of immature hepatocytes to a variety of insults such as cholestasis,2-4 and when it occurs in adults, it is known as postinfantile giant cell hepatitis.2,4,5

Agents that have been associated to this diagnosis include: infections such as hepatitis A, B and C viruses,6 HIV, EBV, and paramyxovirus;7 drugs as methotrexate, 6-mercaptopurine, p-aminosalicylic acid, chlorpromazine, vinyl chloride, clomethacin,2 and a case of GCH after a human herpesvirus 6-induced adverse drug reaction has also been described;4 diseases like sickle cell anemia, autoimmune hemolytic anemia, chronic lymphocytic leukemia,9 non-Hodgkin’s lymphoma involving the liver,4 polyarteritis nodosa,10 autoimmune hepatitis (type I and II11), ulcerative colitis (suggesting that GCH may be included in the list of hepatic complications of inflammatory bowel disease),2,12 primary biliary cirrhosis13 and primary sclerosing cholangitis;3 congenital metabolic diseases such as alpha 1-antitrypsin deficiency or haemoperosiderosis, and in some other cases the etiology remains unclear.

Giant-cell transformation is a nonspecific reaction to various stimuli rather than a specific disease process.4,14 There are two possible mechanisms in the formation of giant hepatocytes: the fusion of individual cells to form a syncytium (therefore the used term «syncytial giant cell hepatitis»15) and the failure of the cytoplasm to divide at the time of nuclear division.4,14

The diagnosis is made when multinucleated syncytial hepatocytes are observed in liver biopsy,3 they may be seen as isolated clusters of giant cells or multinucleated giant cells over mononuclear hepatocytes, appearing predominantly in zone 3 or 1 of the Rappaport acinus. Other histological findings include portal inflammation (more commonly lymphocytic, but plasma cells and neutrophils can also be seen), varying degrees of acinar inflammation, hepatocellular necrosis, ballooning degeneration, bile duct lesions (nonsuppurative destructive cholangitis, periductal scarring, and ductopenia), periportal fibrosis and cirrhosis.4

The clinical course may vary from normalization of hepatic histology, either spontaneously or by medical treatment, to progression to cirrhosis and liver failure.2,3 The prognosis is dictated by the underlying liver disease2,16 and in the setting of autoimmune hepatitis the clinical course is usually severe with most of the patients progressing to cirrhosis. Prolonged treatment with corticosteroids and immunosuppressants is usually effective.
in rendering the cirrhosis inactive. A reduction in the number of giant hepatocytes after treatment of the autoimmune and cholestatic features has been reported previously, which may suggest that an autoimmune mechanism as well as cholestasis may be involved in the pathogenesis of giant cell transformation.\textsuperscript{2-5,17,18}

Most of the patients with GCH have an unfavorable prognosis, with a rapidly progressive course leading to death or the need for orthotopic liver transplantation, although GCH can recur in liver allograft.\textsuperscript{19,20}

References